MMA Announces SMARTIES™ X Global 2025 Winners: Honoring Marketing That Drives Global Impact

MMA Announces SMARTIES™ X Global 2025 Winners: Honoring Marketing That Drives Global Impact

NEW YORK, Dec. 19, 2025 /PRNewswire/ -- The Marketing + Media Alliance (MMA) proudly announces the winners of the SMARTIES™ X Global 2025 Awards, recognizing the world's most effective and innovative marketing campaigns. This year's program...

Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity

Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity

After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding body weight reductions of 7.72 kg and 8.65 kg. These results were significantly superior...

Comarch Named a Strong Performer in Loyalty Platforms Evaluation by Independent Research Firm

Comarch Named a Strong Performer in Loyalty Platforms Evaluation by Independent Research Firm

KRAKÓW, Poland, Dec. 9, 2025 /PRNewswire/ -- Comarch, a global provider of IT solutions and services, today announced its recognition as a Strong Performer in The Forrester Wave™: Loyalty Platforms, Q4 2025. The report, authored by John Pedini,...

Why Transparent, Comparable, and Reliable Security Testing Matters: AV-Comparatives Highlights 2025 Enterprise EPR and EDR Results

Why Transparent, Comparable, and Reliable Security Testing Matters: AV-Comparatives Highlights 2025 Enterprise EPR and EDR Results

INNSBRUCK, Austria, Dec. 9, 2025 /PRNewswire/ -- As cyberattacks continue to challenge even the most resilient organisations, the need for clear, trustworthy, and openly documented security testing has never been more critical. AV-Comparatives,...

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that clinical data from its allogeneic BCMA-targeted CAR T-cell product...

Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density-Driven Risk Modeling at RSNA 2025

Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density-Driven Risk Modeling at RSNA 2025

Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision...

DuPont Innovation Awards Recognize the Best PPE and Fabrics Against Emerging Risks

DuPont Innovation Awards Recognize the Best PPE and Fabrics Against Emerging Risks

Winners demonstrate how Nomex® and Kevlar® fabrics and fibers can advance sustainability, multi-hazard protection, and firefighter safety. DÜSSELDORF, Germany, Nov. 18, 2025 /PRNewswire/ -- DuPont (NYSE: DD) today announced the winners of its 2025...

Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its...

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

OSR Holdings Announces Woori IO's Noninvasive Glucose Monitor Demonstrates High Accuracy and Precision in Company-Sponsored Pilot Study

BELLEVUE, Wash., Nov. 6, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced the key findings from a company-sponsored pilot study conducted by Woori IO, an OSR Company, in collaboration with Korea University Guro Hospital. The...

CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B

CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B

SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T product...

  • 1
  • 2
  • 3
  • 4
  • menu
    menu